LLY-284 is the less potent diastereomer of the potent SAM-competitive PRMT5 inhibitor LLY-283 (IC50 = 20 nM against PRMT5-catalyzed methylation of an H4R3-derived peptide substrate) and an ideal control compound for cellular studies. For characterization details of the active probe, LLY-283, please visit the LLY-283 probe summary on the Structural Genomics Consortium (SGC) website.LLY-283, the active probe, is available from Sigma. To learn more about and purchase LLY-283, click here.To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
Features and Benefits
LLY-284 is a negative control for LLY-283, an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.